Compare DOLE & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DOLE | EVO |
|---|---|---|
| Founded | 1851 | 1993 |
| Country | Ireland | Germany |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 778.3M |
| IPO Year | 2021 | 2007 |
| Metric | DOLE | EVO |
|---|---|---|
| Price | $13.07 | $1.58 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $15.00 | $7.00 |
| AVG Volume (30 Days) | ★ 960.3K | 41.4K |
| Earning Date | 05-11-2026 | 04-08-2026 |
| Dividend Yield | ★ 2.29% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.60 | N/A |
| Revenue | ★ $9,172,907,000.00 | N/A |
| Revenue This Year | $4.93 | $1.37 |
| Revenue Next Year | $1.72 | $10.05 |
| P/E Ratio | $21.95 | ★ N/A |
| Revenue Growth | ★ 8.23 | N/A |
| 52 Week Low | $12.52 | $1.60 |
| 52 Week High | $16.51 | $4.27 |
| Indicator | DOLE | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 37.47 | 28.43 |
| Support Level | $12.74 | N/A |
| Resistance Level | $14.35 | $1.97 |
| Average True Range (ATR) | 0.29 | 0.05 |
| MACD | -0.06 | -0.01 |
| Stochastic Oscillator | 10.34 | 2.70 |
Dole PLC operates in the North American and European markets for fresh fruits and vegetables. The company's segment includes Fresh Fruit; Diversified Fresh Produce - EMEA; Diversified Fresh Produce - Americas and ROW. It generates maximum revenue from the Diversified Fresh Produce - EMEA segment. Diversified Fresh Produce - EMEA segment includes Dole's Irish, Dutch, Spanish, Portuguese, French, Italian, U.K., Swedish, Danish, South African, Eastern European, and Brazilian businesses, the majority of which sell a variety of imported and local fresh fruits and vegetables through retail, wholesale and, in some instances, food service channels across the European marketplace. Geographically, the company operates in United States, Ireland, U.K. Spain, Sweden, and Others.
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.